Home
overview
The increasing demands of global competition within the drug industry are resulting in an increasing amount of progressive strategic alliances to advance the competitive edge. The right strategic alliance, formed through strength, not weakness, can create a powerful impact in the market place.

SMi’s Win-Win Agreements in the Drug Industry conference will focus on partnership agreements across the entire drug industry in which success depends upon managing collaborations effectively and achieving the correct balance. The drug industry has a rapidly developing global strategic network and victory goes to those who build the better network.

As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for SMi’s Win-Win Agreements in the Drug Industry.

Win-Win Agreements in the Drug Industry is organised and produced by SMi: we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry figures and seek their advice and opinions.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Carl F Siekmann

Carl F Siekmann, Executive Vice President, Corporate Development, Sheffield Pharmaceuticals

9:10 COLLABORATIONS IN THE PHARMACEUTICAL & BIOTECH INDUSTRY

Dimitri F Dimitriou

Dimitri F Dimitriou, Senior Director, Worldwide Business Development, SmithKline Beecham

  • Transactions, valuations and the markets in the life sciences
  • Where do you start and what next?
  • Opportunities across the ‘pond’
  • Elements for a win-win partnership
  • Structuring the ‘right’ agreement
  • 9:40 WHY PARTNER?

    Dr Stephen Castle

    Dr Stephen Castle, Managing Director, Europe, Mattson Jack Group

  • Portfolio/Life cycle planning - ensuring profitable growth
  • Identifying needs, gaps and fillers - and their associated value
  • Factors to consider in developing a therapeutic franchise
  • Resource scoping - internal and external
  • Partnering possibilities
  • 10:20 MANAGING ALLIANCE SUCCESS

    Dr David McCamey

    Dr David McCamey, Senior Manager, Alliance Effectiveness, Procter & Gamble

  • What is different about alliance management?
  • Building alliance management capability
  • Alliance effectiveness success factors
  • Tools you can use
  • Examples
  • 11:00 Morning Coffee

    11:20 VALUING A LICENSING ARRANGEMENT

    Khawar Mann

    Khawar Mann, Director, Business Development, Weston Medical

  • Motivations for entering into licensing arrangements
  • Characteristics of the deal
  • Valuation parameters
  • Making the deal work
  • Examples from Weston Medical's experience
  • 12:00 INTELLECTUAL PROPERTY RIGHTS AND OWNERSHIP ISSUES

    Nigel Jones

    Nigel Jones, Head, Healthcare Group, Linklaters & Alliance

  • What rights are important?
  • Due diligence issues
  • Key contractual terms concerning IPRs
  • Competition law considerations
  • 12:40 Lunch

    Sponsored by Dura Pharmaceuticals

    Sponsored by Dura Pharmaceuticals, ,

    13:40 SUCCESSFUL PARTNERSHIP AGREEMENTS

    Andrew Silverthorne

    Andrew Silverthorne, Head, Business Development, CeNeS

  • Identifying key elements
  • Objectives of the parties
  • Structure of successful collaborations
  • Advantages of collaborations
  • Common problems in reaching a mutually acceptable agreement
  • 14:20 RISK MANAGEMENT IN PHARMACEUTICAL PARTNERSHIP AGREEMENTS

    Hannes T Smarason

    Hannes T Smarason, Senior Vice President, Chief Business Officer, DeCode Genetics

  • Understanding risks involved
  • Risk management techniques
  • Applying effective risk management
  • Assessing risk in partnership agreements
  • Financial Implications
  • Case Study
  • 15:00 WHAT IS THE FUTURE FOR DEALS?

    Dr Fintan Walton

    Dr Fintan Walton, Chief Executive Officer, PharmaVentures

  • What are the trends in deals?
  • Analysis of recent deals
  • What is the future basis for deals?
  • Who will be the winners?
  • Case Study
  • 15:40 Afternoon Tea

    16:00 COLLABORATIVE PRODUCT DEVELOPMENT AND ALLIANCE MANAGEMENT

    Mark Mugerditchian

    Mark Mugerditchian, Senior Director, Insulin Business, Dura Pharmaceuticals

  • Criteria for consideration in the design of a Product Development Alliance
  • Benefits of Product Development Alliances
  • Strengthening the research collaboration
  • Areas of leverage that are unique to Product Development Alliances
  • A case study of a Product Development Alliance; successes and challenges for the future
  • 16:30 SEARCH AND COMPLETION PROCESSES

    Björn Dellgren

    Björn Dellgren, Director, New Business & Strategic Planning, Pharmacia Consumer Healthcare

  • Clear strategic directions
  • Targeted search process
  • Evaluation phase
  • Valuation models
  • Decision making and responsibilities
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Drinks reception for speakers and delegates

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr James New

    Dr James New, Head of Global Business Development & Licensing, Novartis

    9:10 ALLIANCES FOR DISCOVERY AND DEVELOPMENT

    Dr Trevor Jarman

    Dr Trevor Jarman, Director, Business Development, Alizyme

  • Strategic focus and opportunity selection
  • Securing and evolving agreements
  • Adding value and balancing risk
  • Right partner, right deal, right time
  • 9:40 VIRTUAL DRUG R&D

    Dr David Cavalla

    Dr David Cavalla, Chief Executive Officer, Arachnova

  • Industrial sector framework
  • Strategies in virtual drug discovery: types of virtuality
  • Limiting risk
  • Developing networks
  • Therapeutic switching
  • 10:20 TECHNOLOGY COLLABORATIONS

    Dr Rivka Sherman-Gold

    Dr Rivka Sherman-Gold, Director, Business Development, Abgenix

  • Generating human antibodies to several disease targets
  • Dividing responsibility for R&D, manufacturing and marketing
  • Building and commercialising a diversified product portfolio
  • Establishing corporate collaborations to fulfil the business strategy
  • The importance of multiple partnership agreements
  • Managing multiple collaborations
  • 11:00 Morning Coffee

    11:20 MULTI-PRODUCT COLLABORATIONS

    Pauline Jen Ryan

    Pauline Jen Ryan, Vice President, Business Development, ImmunoGen

  • Leveraging the technology platform
  • Accessing the tumour-activated pro-drug (TAP) technology
  • Combining technology for improved drug development of cancer therapeutics
  • Creatively structuring the collaboration
  • Benefits for both companies
  • Developing the business strategy through collaboration
  • 12:00 JOINT VENTURES FOR DEVELOPING THE NEXT GENERATION OF CANCER DRUGS

    Dr Björn Nordenvall

    Dr Björn Nordenvall, President & Chief Executive Officer, OXiGENE

  • Advantages of joint ventures
  • Techniclone’s vascular targeting agent (VTA)
  • Joint venture combination strategy
  • Supplying the intellectual property
  • Providing the expertise
  • Collaborating on R&D
  • 12:40 Lunch

    14:00 PHARMACOGENOMIC DEALS IN THE NEW MILLENNIUM

    Dr James S Kuo

    Dr James S Kuo, Vice President, Worldwide Business Development, Genset

  • What actually is pharmacogenomics?
  • Why all the interest in pharmacogenomics now?
  • How pharmacogenomics can be applied throughout the drug development process
  • Successfully marketing pharmacogenomic programmes to large pharma
  • Unique structural aspects of win-win pharmacogenomic deals
  • 14:40 MAKING DEALS WORK

    Dr Bart Wuurman

    Dr Bart Wuurman, Director, Business Development, Antisoma

  • Building an effective collaboration
  • Cultural differences
  • Trouble shooting
  • Examples
  • 15:20 Afternoon Tea

    15:40 PERFORMANCE IN CLINICAL DEVELOPMENT

    Christopher Bailey

    Christopher Bailey, Director, OHM Clinical Studies Centre

  • The importance of organisation at the investigator site level
  • The risks an investigator organisation might take
  • Re-engineering the investigator contract for risk sharing
  • Setting up a clinical trial for shared risk achievement
  • A case study in a Hormone Replacement Therapy trial
  • 16:00 OUTSOURCING RESOURCES

    Mark S Masento

    Mark S Masento, Business Development Manager, Pharmalytic

  • Using contract services in the project matrix
  • Analytical laboratories - a key example
  • Critical areas of analytical support
  • Assuring seamless regulatory compliance
  • Communication - banishing fear, building trust
  • Criteria for win-win outcomes
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Partnership in the Bio/Pharma Sector – a Practical Workshop
    Workshop

    Partnership in the Bio/Pharma Sector – a Practical Workshop

    The Hatton, at etc. venues
    27th October 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.